Crescent Biopharma (CBIO) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 8.0% versus a loss of 0.5%. Over five years, DSGN leads with a -49.3% price change compared with -92.7% for CBIO. Design Therapeutics is the larger company by market cap ($577.6 million vs $543.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | DSGN |
|---|---|---|
| Share price | $13.00 | $9.02 |
| Market cap | $543.21M | $577.61M |
| 1-day change | +0.70% | -3.22% |
| YTD return | +9.61% | -3.84% |
| 1-year return | -0.46% | +8.02% |
| 5-year return | -92.74% | -49.27% |
| EPS (TTM) | $-7.29 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.84M | $0 |
| Net income (latest FY) | $-153.94M | $-69.79M |
| Operating margin | -1407.52% | — |
| Net margin | -1419.61% | — |
| 52-week high | $27.41 | $17.25 |
| 52-week low | $8.72 | $8.21 |
| Distance from 52-week high | -52.57% | -47.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +148.69% | +139.14% |
| Average volume | 361.17K | 554.69K |
| Shares outstanding | 38.90M | 64.04M |
| Employees | 80 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
CBIO vs DSGN FAQ
Which is bigger, Crescent Biopharma or Design Therapeutics?
Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $543.21M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or DSGN?
DSGN returned +8.02% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.